Table 3

GEE results (OR (95% CI)) for the outcomes erosion progression, joint space narrowing progression and Sharp–van der Heijde progression yes/no, showing a dose response for swelling and tenderness

Erosion progressionJSN progressionSHS progression
Swollen neverReferenceReferenceReference
 Swollen, 1×1.4 (1.00 to 2.3)1.7 (1.2 to 2.4)1.5 (1.2 to 2.0)
 Swollen, ≥2×3.0 (2.0 to 4.5)3.2 (2.1 to 4.8)2.7 (2.0 to 3.7)
Tender neverReferenceReferenceReference
 Tender, 1×1.6 (1.03 to 2.4)1.4 (0.94 to 2.1)1.5 (1.1 to 2.1)
 Tender, ≥2×3.9 (2.6 to 5.9)3.7 (2.2 to 5.2)3.3 (2.4 to 4.5)
  • All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression) JSN at baseline yes/no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), age, gender, body mass index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, double negative), treatment group and erythrocyte sedimentation rate.

  • CCP, cyclic citrullinated peptide; GEE, generalised estimating equations; JSN, joint space narrowing; SHS, Sharp–van der Heijde score.